Ultragenyx Pharmaceutical (RARE)
(Real Time Quote from BATS)
$45.27 USD
+0.81 (1.82%)
Updated Jul 16, 2024 09:58 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 241 - 260 ( 333 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Greenlight for Early UX007 Filing is a Surprise, Updating our Program Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Initial Launch Metrics should Allay Key Concerns over Crysvita
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Crysvita Launch Underway, We Remain Positive on Long- Term Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Positive Label and Pricing Strengthens Commercial Outlook for Crysvita
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
''301 Benefit Durable in 1st Patient, Broader Activity Expected at Higher Doses
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Slow Crysvita Adoption Expected in 2018, Long-Term Outlook Remains Promising
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.